Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
ConclusionsIn these patients with T2DM, cangrelor was comparable to clopidogrel in terms of efficacy at 48 h following PCI. However, it was associated with significantly higher mild GUSTO bleeding and major and minor ACUITY bleeding, therefore requiring further workups on its safety side. This hypothesis should be explored further and confirmed in other forthcoming trials based strictly on patients wit h T2DM.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Percutaneous Coronary Intervention | Plavix | Thrombosis